Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation
- PMID: 10098487
- DOI: 10.1210/endo.140.4.6667
Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation
Abstract
It has been well established that the spiroindoline sulfonamide MK-0677 stimulates GH secretion from the pituitary both in vitro and in vivo. MK-0677 has also been shown to increase serum insulin-like growth factor I (IGF-I) and cortisol levels in vivo; these increases are assumed to be driven by the increased serum GH and ACTH levels, respectively. However, such increases could also be due to a direct stimulatory action of MK-0677 at the level of the liver and adrenal cortex. To address this possibility, we investigated whether MK-0677 increased IGF-I and cortisol levels in hypophysectomized dogs. Baseline GH, IGF-I, and cortisol responses to MK-0677 (1 mg/kg, orally) were initially determined. Hypophysectomy (hypox; n = 7) or sham surgery (sham; n = 5) was then carried out. Six days postsurgery, the GH and cortisol responses to MK-0677 were reevaluated in each dog. In addition, each dog was treated with porcine GH (PST; 0.1 IU/kg, s.c.) to confirm the responsiveness of the GH-IGF-I axis. The mean peak GH increases in response to MK-0677 in the presham dogs (83.7 +/- 19.2 ng/ml), post-sham dogs (108 +/- 26.2 ng/ml), and pre-hypox dogs (121.2 +/- 13.6 ng/ml) were not significantly different. Mean peak GH levels were unchanged after MK-0677 administration in the hypox dogs (2.3 +/- 0.7 ng/ml). Before surgery, serum IGF-I levels increased to 243 +/- 27 and 224 +/- 47 ng/ml in the sham and hypox groups, respectively, after MK-0677 administration. Surgery was associated with a marked (> or =50%) decrease in serum IGF-I levels. MK-0677 administration increased IGF-I levels in the sham dogs from 78 +/- 14 to 187 +/- 31 ng/ml, whereas IGF-I levels remained unchanged (17.7 +/- 2.4 ng/ml) in the-hypox dogs. PST treatment increased IGF-I levels in the sham dogs from 162 +/- 30 to 325 +/- 32 ng/ml. In the hypox dogs PST treatment restored IGF-I to physiological levels (from 17.7 +/- 2.4 to 199 +/- 41 ng/ml). Cortisol was increased after MK-0677 administration 3.7-fold in the pre-sham, 3.6-fold in the post-sham, and 3.6-fold in the pre-hypox dogs, but no increase was seen in the post-hypox dogs. ACTH GEL administration (2.2 U/kg, i.m.) to hypox dogs returned cortisol to normal physiological levels, demonstrating the functional integrity of the adrenal cortex. This study demonstrates that the GH secretagogue MK-0677 does not directly stimulate an increase in serum IGF-I or cortisol levels, but depends upon the presence of an intact pituitary.
Similar articles
-
MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.Endocrinology. 1996 Dec;137(12):5284-9. doi: 10.1210/endo.137.12.8940347. Endocrinology. 1996. PMID: 8940347
-
Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles.J Endocrinol. 1997 Feb;152(2):183-92. doi: 10.1677/joe.0.1520183. J Endocrinol. 1997. PMID: 9071975
-
Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration.Horm Metab Res. 1999 Feb-Mar;31(2-3):133-7. doi: 10.1055/s-2007-978710. Horm Metab Res. 1999. PMID: 10226793
-
Growth promotion by insulin-like growth factor I in hypophysectomized and diabetic rats.Mol Cell Endocrinol. 1998 May 25;140(1-2):143-9. doi: 10.1016/s0303-7207(98)00042-2. Mol Cell Endocrinol. 1998. PMID: 9722182 Review.
-
Cortisol and GH: odd and controversial ideas.Appl Physiol Nutr Metab. 2007 Oct;32(5):895-903. doi: 10.1139/H07-064. Appl Physiol Nutr Metab. 2007. PMID: 18059614 Review.
Cited by
-
GH-releasing peptide (GHRP-6)-induced ACTH release in patients with addison's disease: effect of glucocorticoid withdrawal.J Endocrinol Invest. 2003 Feb;26(2):143-7. doi: 10.1007/BF03345143. J Endocrinol Invest. 2003. PMID: 12739742 Clinical Trial.
-
GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.J Endocrinol Invest. 2003 Mar;26(3):230-5. doi: 10.1007/BF03345162. J Endocrinol Invest. 2003. PMID: 12809173 Clinical Trial.
-
Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats.Yonsei Med J. 2018 Dec;59(10):1174-1180. doi: 10.3349/ymj.2018.59.10.1174. Yonsei Med J. 2018. PMID: 30450851 Free PMC article.
-
Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.J Endocrinol Invest. 2001 Feb;24(2):67-71. doi: 10.1007/BF03343815. J Endocrinol Invest. 2001. PMID: 11263473 Clinical Trial.
-
Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis.Pituitary. 2009;12(4):315-21. doi: 10.1007/s11102-009-0181-3. Epub 2009 Apr 26. Pituitary. 2009. PMID: 19396632 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources